## 17 PATIENT COUNSELING INFORMATION

Administration

Advise patients to take XOLREMDI on an empty stomach after an overnight fast, 30 minutes before

food. Advise patients to swallow the capsules whole and not to open, break, or chew capsules _[see Dosage and Administration (2.1) and Clinical Pharmacology (12.3)]_.

Embryo-Fetal Toxicity

XOLREMDI is expected to cause fetal harm. Advise females of reproductive potential to use an effective form of contraception during treatment with XOLREMDI and for three weeks after the final dose. Advise females to inform their healthcare provider of a known or suspected pregnancy _[see Warnings and Precautions (5.1) and Use In Specific Populations (8.1)]_.

Lactation

Advise females that breastfeeding is not recommended during treatment with XOLREMDI and for three weeks after the final dose _[see Use in Specific Populations (8.2)]_.

Drug Interactions

Advise patients to avoid taking dietary supplements that include goldenseal, as it is a strong CYP3A4 inhibitor and may increase risk of adverse reactions from XOLREMDI.

Advise patients to avoid taking dietary supplements that include St. Johnâ€™s Wort, as it is an inducer of CYP3A4 and may reduce the efficacy of XOLREMDI _[see Drug Interactions (7.2)]_.

Food Interactions

Advise patients to avoid eating or drinking products with grapefruit, as grapefruit is a strong CYP3A4 inhibitor and may increase the risk of adverse reactions from XOLREMDI _[see Drug Interactions (7.1)]_.

Manufactured for:

X4 Pharmaceuticals, Inc. Boston, MA 02134
Reference ID: 5371673
